NS 50210/NS/NINDS NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2006	1
2008	3
2009	3
2010	1
2011	3
2013	1
2024	0

1

RNA polymerase III transcribes human microRNAs.

Borchert GM, Lanier W, Davidson BL. Borchert GM, et al. Nat Struct Mol Biol. 2006 Dec;13(12):1097-101. doi: 10.1038/nsmb1167. Epub 2006 Nov 12. Nat Struct Mol Biol. 2006. PMID: 17099701

2

Altered Purkinje cell miRNA expression and SCA1 pathogenesis.

Rodriguez-Lebron E, Liu G, Keiser M, Behlke MA, Davidson BL. Rodriguez-Lebron E, et al. Neurobiol Dis. 2013 Jun;54:456-63. doi: 10.1016/j.nbd.2013.01.019. Epub 2013 Jan 30. Neurobiol Dis. 2013. PMID: 23376683 Free PMC article.

3

Splice isoform-specific suppression of the Cav2.1 variant underlying spinocerebellar ataxia type 6.

Tsou WL, Soong BW, Paulson HL, Rodríguez-Lebrón E. Tsou WL, et al. Neurobiol Dis. 2011 Sep;43(3):533-42. doi: 10.1016/j.nbd.2011.04.016. Epub 2011 Apr 29. Neurobiol Dis. 2011. PMID: 21550405 Free PMC article.

4

Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.

Rodríguez-Lebrón E, Gouvion CM, Moore SA, Davidson BL, Paulson HL. Rodríguez-Lebrón E, et al. Mol Ther. 2009 Sep;17(9):1563-73. doi: 10.1038/mt.2009.123. Epub 2009 Jun 16. Mol Ther. 2009. PMID: 19532137 Free PMC article.

5

Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice.

Piedrahita D, Hernández I, López-Tobón A, Fedorov D, Obara B, Manjunath BS, Boudreau RL, Davidson B, Laferla F, Gallego-Gómez JC, Kosik KS, Cardona-Gómez GP. Piedrahita D, et al. J Neurosci. 2010 Oct 20;30(42):13966-76. doi: 10.1523/JNEUROSCI.3637-10.2010. J Neurosci. 2010. PMID: 20962218 Free PMC article.

6

Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.

Boudreau RL, Martins I, Davidson BL. Boudreau RL, et al. Mol Ther. 2009 Jan;17(1):169-75. doi: 10.1038/mt.2008.231. Epub 2008 Nov 11. Mol Ther. 2009. PMID: 19002161 Free PMC article.

7

Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs.

Boudreau RL, Monteys AM, Davidson BL. Boudreau RL, et al. RNA. 2008 Sep;14(9):1834-44. doi: 10.1261/rna.1062908. Epub 2008 Aug 12. RNA. 2008. PMID: 18697922 Free PMC article.

8

Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

Boudreau RL, Spengler RM, Davidson BL. Boudreau RL, et al. Mol Ther. 2011 Dec;19(12):2169-77. doi: 10.1038/mt.2011.185. Epub 2011 Sep 27. Mol Ther. 2011. PMID: 21952166 Free PMC article.

9

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, Davidson BL. Boudreau RL, et al. Mol Ther. 2009 Jun;17(6):1053-63. doi: 10.1038/mt.2009.17. Epub 2009 Feb 24. Mol Ther. 2009. PMID: 19240687 Free PMC article.

10

Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.

McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ, Davidson BL. McBride JL, et al. Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5868-73. doi: 10.1073/pnas.0801775105. Epub 2008 Apr 8. Proc Natl Acad Sci U S A. 2008. PMID: 18398004 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

11 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year